Balyasny Asset Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Balyasny Asset Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,151,518	Closed	-$78.4M	–	3574
2022 Q3	$78.4M	Buy	+1,151,518	New	+$63.5M	0.24%	85
2022 Q1	–	Sell	-104,154	Closed	-$3.05M	–	3027
2021 Q4	$3.05M	Buy	+104,154	New	+$3.23M	0.01%	1032
2019 Q2	–	Sell	-172,948	Closed	-$9.15M	–	1807
2019 Q1	$9.15M	Sell	172,948 -22,645	-12%	-$1.11M	0.06%	411
2018 Q4	$8.03M	Buy	195,593 +188,991	+2,863%	+$7.08M	0.06%	402
2018 Q3	$251K	Sell	6,602 -41,972	-86%	-$1.86M	﹤0.01%	1544
2018 Q2	$2.2M	Sell	48,574 -44,146	-48%	-$2.01M	0.01%	904
2018 Q1	$4.48M	Buy	+92,720	New	+$5.17M	0.02%	742
2017 Q4	–	Sell	-8,677	Closed	-$269K	–	2405
2017 Q3	$269K	Buy	+8,677	New	+$244K	﹤0.01%	1581
2016 Q2	–	Sell	-30,300	Closed	-$481K	–	1527
2016 Q1	$481K	Buy	+30,300	New	+$538K	﹤0.01%	898

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Balyasny Asset Management's GBT Position: Q4 2022 in Review

Balyasny Asset Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,151,518 shares — an estimated $78.4M sold.

Balyasny Asset Management first reported a position in GBT in Q1 2016 and held it in 9 quarters. The position peaked at $78.4M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Balyasny Asset Management reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Balyasny Asset Management sold 1,151,518 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $78.4M.
Balyasny Asset Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2016 and held it in 9 quarters.
Balyasny Asset Management's Global Blood Therapeutics, Inc. position peaked at $78.4M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.